Wet Age-related Macular Degeneration

• FDA approval · 2025-02-03
  FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for SUSVIMO (ranibizumab) submitted by Genentech, Inc. The action relates to a regulatory update…

• FDA approval · 2023-12-14
  FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc.

• FDA approval · 2022-02-18
  FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for BEOVU (brolucizumab) submitted by Novartis Pharmaceuticals Corporation.

• FDA approval · 2021-10-22
  FDA Approved: SUSVIMO — Original Application (Genentech, Inc.)

  FDA approved SUSVIMO, a port delivery system delivering ranibizumab, for the treatment of wet age-related macular degeneration.

• FDA approval · 2019-08-12
  FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

  The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indi…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.